HPA021319

antibody from Atlas Antibodies

Targeting: SAMD9 C7orf5, FLJ20073, KIAA2004

Western blot (Data presented on provider website)

Immunocytochemistry (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

HPA021319

Provider

Atlas Antibodies

Proper citation

Atlas Antibodies Cat#HPA021319, RRID:AB_1856554

Product name

Anti-SAMD9

Antibody type

Polyclonal

Description

Polyclonal Antibody against Human SAMD9, Gene description: sterile alpha motif domain containing 9, Alternative Gene Names: C7orf5, FLJ20073, KIAA2004, Validated applications: WB, IHC, ICC, Uniprot ID: Q5K651, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

100 µl

Concentration

0.5 mg/ml

Storage

Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Handling

The antibody solution should be gently mixed before use.

References

Submitted references

Myxoma virus lacking the host range determinant M062 stimulates cGAS-dependent type 1 interferon response and unique transcriptomic changes in human monocytes/macrophages

Bartee E, Conrad S, Raza T, Peterson E, Liem J, Connor R, Nounamo B, Cannon M, Liu J
PLOS Pathogens 2022;18(9):e1010316

---

Non-replicating Vaccinia Virus TianTan Strain (NTV) Translation Arrest of Viral Late Protein Synthesis Associated With Anti-viral Host Factor SAMD9.

Zhao Y, Zhao L, Huang P, Ren J, Zhang P, Tian H, Tan W
Frontiers in cellular and infection microbiology 2020;10:116

---

RNA granules associated with SAMD9-mediated poxvirus restriction are similar to antiviral granules in composition but do not require TIA1 for poxvirus restriction

Meng X, Xiang Y
Virology 2019;529

---

An interaction domain in human SAMD9 is essential for myxoma virus host-range determinant M062 antagonism of host anti-viral function

Nounamo B, Li Y, O’Byrne P, Kearney A, Khan A, Liu J
Virology 2017;503

---

Somatic mutations and progressive monosomy modify SAMD9-related phenotypes in humans

Buonocore F, Kühnen P, Suntharalingham J, Del Valle I, Digweed M, Stachelscheid H, Khajavi N, Didi M, Brady A, Blankenstein O, Procter A, Dimitri P, Wales J, Ghirri P, Knöbl D, Strahm B, Erlacher M, Wlodarski M, Chen W, Kokai G, Anderson G, Morrogh D, Moulding D, McKee S, Niemeyer C, Grüters A, Achermann J
Journal of Clinical Investigation 2017;127(5):1700-1713

---

SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7

Narumi S, Amano N, Ishii T, Katsumata N, Muroya K, Adachi M, Toyoshima K, Tanaka Y, Fukuzawa R, Miyako K, Kinjo S, Ohga S, Ihara K, Inoue H, Kinjo T, Hara T, Kohno M, Yamada S, Urano H, Kitagawa Y, Tsugawa K, Higa A, Miyawaki M, Okutani T, Kizaki Z, Hamada H, Kihara M, Shiga K, Yamaguchi T, Kenmochi M, Kitajima H, Fukami M, Shimizu A, Kudoh J, Shibata S, Okano H, Miyake N, Matsumoto N, Hasegawa T
Nature Genetics 2016;48(7):792-797

---

miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9

WU L, PU X, WANG Q, CAO J, XU F, XU L, LI K
Oncology Letters 2016;11(2):945-952